Interstitial pneumonia with autoimmune features : An additional risk factor for ARDS? by G. Grasselli et al.
Grasselli et al. Ann. Intensive Care  (2017) 7:98 
DOI 10.1186/s13613-017-0320-3
RESEARCH
Interstitial pneumonia with autoimmune 
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Abstract 
Background: Interstitial pneumonia with autoimmune features (IPAF) identifies a recently recognized autoimmune 
syndrome characterized by interstitial lung disease and autoantibodies positivity, but absence of a specific connec-
tive tissue disease diagnosis or alternative etiology. We retrospectively reviewed the clinical presentation, diagnostic 
workup and management of seven critically ill patients who met diagnostic criteria for IPAF. We compared baseline 
characteristics and clinical outcome of IPAF patients with those of the population of ARDS patients admitted in the 
same period.
Results: Seven consecutive patients with IPAF admitted to intensive care unit for acute respiratory distress syndrome 
(ARDS) were compared with 78 patients with ARDS secondary to a known risk factor and with eight ARDS patients 
without recognized risk factors. Five IPAF patients (71%) survived and were discharged alive from ICU: Their survival 
rate was equal to that of patients with a known risk factor (71%), while the subgroup of patients without risk factors 
had a markedly lower survival (38%). According to the Berlin definition criteria, ARDS was severe in four IPAF patients 
and moderate in the remaining three. All had multiple organ dysfunction at presentation. The most frequent autoan-
tibody detected was anti-SSA/Ro52. All patients required prolonged mechanical ventilation (median duration 49 days, 
range 10–88); four received extracorporeal membrane oxygenation and one received low-flow extracorporeal  CO2 
removal. All patients received immunosuppressive therapy.
Conclusions: This is the first description of a cohort of critical patients meeting the diagnostic criteria for IPAF 
presenting with ARDS. This diagnosis should be considered in any critically ill patient with interstitial lung disease of 
unknown origin. While management is challenging and level of support high, survival appears to be good and com-
parable to that of patients with ARDS associated with a known clinical insult
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Background
The term “connective tissue disease” (CTD) refers to a 
heterogeneous group of disease that targets the con-
nective tissues of the body. The autoimmune CTDs are 
caused by overactivity of the immune system, result-
ing in the production of autoantibodies. Their diag-
nosis is based on the combination of clinical history, 
physical examination and laboratory and radiologic find-
ings, according to the established diagnostic criteria [1, 
2].
Clinical presentation ranges from mild symptoms to 
life-threatening manifestations. Up to 30% of patients 
with CTD require intensive care unit (ICU) admission, 
and the CTD is frequently diagnosed during the ICU stay 
[3, 4]. The main reason for ICU admission is acute respir-
atory failure (ARF): type and frequency of lung involve-
ment vary among the different CTDs [5], but a typical 
presentation is represented by interstitial lung disease 
(ILD) [6, 7].
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The early recognition of the etiology of ILD (CTD, envi-
ronmental exposures, drugs or idiopathic conditions) is 
crucial to choose the appropriate therapeutic strategy but 
can be really challenging. Nonetheless, a significant num-
ber of patients with ILD have clinical and/or serologic 
features suggesting an autoimmune etiology but do not 
fulfill established diagnostic criteria for a definite CTD: 
In these cases, different definitions have been proposed 
like undifferentiated CTD (UCTD) [8, 9], lung-dominant 
CTD (LD-CTD) [10, 11] and autoimmune-featured ILD 
(AIF-ILD) [12], but none of these is universally accepted. 
Recently, a consensus on the term “interstitial pneumo-
nia with autoimmune features” (IPAF) has been reached 
by a joint European Respiratory Society (ERS)–American 
Thoracic Society (ATS) task force [13].
We present here for the first time a series of seven 
patients meeting the diagnostic criteria for IPAF requir-
ing ICU admission for acute respiratory distress syn-
drome (ARDS) and multiple organ failure. Baseline 
characteristics and clinical outcome of IPAF patients 
were compared with those of the population of ARDS 
patients admitted in the same period.
Methods
Patient population
We retrospectively reviewed the electronic files of 
patients with a diagnosis of ARDS (according to the Ber-
lin definition criteria) [14] admitted to the tertiary level 
ICUs of San Gerardo Hospital in Monza and of Fondazi-
one IRCCS Ca’ Granda Ospedale Maggiore Policlinico in 
Milan (Italy) from May 2012 to October 2016. Based on 
the presence or absence of a recognized risk factor for 
ARDS among those listed in the Berlin definition crite-
ria [14], patients were subdivided into two groups: (1) 
patients with a known risk factor; (2) patients without 
a known risk factor. The latter group was further subdi-
vided into two subgroups according to the presence of 
diagnostic criteria for IPAF  [13]: a. patients with IPAF 
(study group); b. patients without both a recognized risk 
factor and not fulfilling the criteria for IPAF.
The following data at ICU admission were recorded: 
demographics (sex, age), comorbidities, severity scores 
(SAPSII and SOFA), risk factors for ARDS,  PaO2/FiO2 
(P/F) ratio, intrapulmonary shunt (Qs/Qt), ventilator and 
respiratory mechanics parameters [positive end-expira-
tory pressure (PEEP), tidal volume (Vt), plateau pressure 
(Pplat), driving pressure (ΔP), respiratory rate (RR), static 
respiratory system compliance (Crs)].
Pplat was measured during an end-inspiratory pause of 
at least 2 s ; ΔP was defined as Pplat − PEEPtot; static Crs 
was calculated as Vt/ΔP.
The following outcome data were collected: use of 
prone positioning, need for extracorporeal membrane 
oxygenation (ECMO) support, duration of invasive 
mechanical ventilation (IMV) and ECMO (if applicable), 
ICU length of stay (ICU-LOS) and ICU mortality.
IPAF was diagnosed according to the criteria described 
by the joint ATS–ERS task force (Table S1) [13].
In all patients with IPAF (study group) and with ARDS 
without known risk factors, computed tomography (CT) 
of the chest and bronchoalveolar lavage (BAL) were per-
formed within 2 days from ICU admission, and their find-
ings were reviewed according to the ATS Guidelines [15, 
16]. Timing, dose and schedule of administration of ster-
oid therapy and other eventual immunosuppressive treat-
ments were recorded. Episodes of ventilator-associated 
pneumonia (VAP) occurring in IPAF patients were ana-
lyzed. Finally, in patients with IPAF we obtained long-term 
follow-up data on lung morphology (by CT scan), respira-
tory function (by spirometry) and immunological status.
Statistical analysis
Data are presented as absolute frequency (% of the 
included patients) or as median and interquartile range. 
To evaluate differences between patients’ groups, the 
Kruskal–Wallis test and Pearson’s Chi-squared test were 
utilized to compare continuous and nominal variables, 
respectively. Two-tailed values of p below 0.05 were con-
sidered statistically significant. The JMP 11 statistical 
program (SAS Institute Inc, Cary, NC) was used for sta-
tistical analysis.
Results
Data from 93 patients with ARDS were reviewed. As pre-
viously described, patient population was subdivided into 
three groups (Fig. 1): (1) patients with a known risk fac-
tor for ARDS (n =  78); (2) patients without risk factors 
but fulfilling the diagnostic criteria for IPAF (n = 7); (3) 
patients without risk factors and not meeting the criteria 
for IPAF (n = 8).
Among the 78 patients with ARDS secondary to a 
known clinical insult, pneumonia was the most frequent 
risk factor (47 cases, 13 of viral origin), as shown in Fig. 1.
Description of IPAF patients
Seven patients (four males and three females) with ARF 
due to a newly diagnosed ILD meeting the diagnostic cri-
teria for IPAF were identified. Median age was 61 years 
(IQR 55–64); median SAPS II and SOFA scores at admis-
sion were 32 (32–36) and 11 (11–12.5), respectively. Five 
patients (71%) survived: Their median ICU stay was 54 
(23–78) days and they were all discharged alive from 
the hospital. Two patients died 72 and 23 days after ICU 
admission, respectively (Table 1).
All patients were admitted to the hospital for acute 
dyspnoea and hypoxemia. Extrathoracic symptoms were 
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few and nonspecific (fatigue, weight loss, fever), and none 
had skin lesions or arthritis. No patient had previous his-
tory of ILD and/or CTD, and detailed medication and 
occupational history were negative.
According to the oxygenation criteria established by 
the Berlin definition [14], three patients had moder-
ate and four had severe acute respiratory distress syn-
drome (ARDS); however, in none of them a “known 
clinical insult” [14] could be identified as the cause of 
ARDS. At admission, median P/F ratio was 120  mmHg 
(range 80–163) and median respiratory system compli-
ance 26 ml/cmH2O. All patients required intubation and 
invasive mechanical ventilation (MV). At first day of MV, 
median positive end-expiratory pressure (PEEP) was 12 
 cmH2O, plateau airway pressure 26  cmH2O and tidal vol-
ume 380 mL (Table 1). The time course of selected param-
eters during the ICU stay is depicted in Additional file 1: 
Figure S1. The following rescue therapies were applied: 
recruitment maneuvers (all patients), inhaled nitric oxide 
(three patients) and prone positioning (four patients). 
The median duration of MV was 49 days (21–81) and six 
subjects (85%) were tracheostomized. Five patients (71%) 
required an extracorporeal respiratory support with veno-
venous extracorporeal membrane oxygenation (ECMO) 
in four cases and with low-flow extracorporeal  CO2 
removal  (ECCO2R) with a dedicated device (Prolung™, 
Estor) in one case. Three of these patients survived and 
the median ECMO duration was 53 days (17–63).
All patients needed vasopressor support during the 
ICU stay and two presented with shock at admission. 
One patient required continuous renal replacement 
therapy.
Bacterial, viral or fungal infections were excluded in all 
patients by means of a complete microbiological workup, 
consisting of cultural, serological and molecular biology 
tests on blood, urine and BAL samples.
Other potentially reversible causes, such as pneumo-
thorax, pulmonary embolism, left heart failure, acute 
eosinophilic pneumonia and hypersensitivity pneumonia, 
were ruled out.
Findings of BAL samples and CT scans are detailed 
in Table  2. Briefly, cytomorphological analysis of BAL 
showed mixed alveolitis with significant lymphocytosis 
(>30%) in three cases and significant neutrophilia (>50%) 
in two other patients, without signs of viral inclusion or 
diffuse alveolar hemorrhage.
At CT scans,  consolidations were present in all cases 
and mainly found in subpleural caudal areas, often 
associated with perilobular opacities (Fig.  2a; Addi-
tional file 1: Figure S2). Ground-glass opacities, in some 
cases with subpleural sparing, were also quite common 
but more diffuse and predominant at follow-up scans 
(Fig.  2b; Additional file  1: Figure S2). In four patients, 
mediastinal or hilar lymphadenopathies (with a diameter 
greater than 10 mm) were observed, while pleural effu-
sion was present in only one case. Of the five patients 
who survived, two had limited or widespread organizing 
pneumonia (OP) consolidations; one had typical fea-
tures of AIP/DAD with ground-glass opacities, patchy 
consolidations and fibrotic changes; one had extensive 
ground-glass opacities in lower lobes with some cysts 
suggestive of lymphocytic interstitial pneumonia (LIP) 
but with atypical extensive superimposition of “crazy-
paving” pattern; the last one had and OP/nonspecific 
ARDS with a common risk 
factor (n = 78)
- Pneumonia, n = 48(60%) of 
which 13 H1N1
- septic shock, n = 13(17%)
- inhalation, n = 5(6%)
- vasculitis, n = 5(6%)
- transfusion, n = 3(4%)
- trauma, n = 3(4%)
- pancreatitis, n = 1(1%)
ARDS patients (n = 93)
ARDS without a common risk 
factor (n = 15)
No risk factors 
No IPAF
(n = 8)
IPAF
(n = 7)
Fig. 1 Patient population
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interstitial pneumonia (NSIP) overlap pattern. Both 
patients who died had an OP pattern at presentation, but 
in one of them the initial OP pattern rapidly progressed 
to acute interstitial pneumonia/diffuse alveolar dam-
age (AIP/DAD) pattern and he subsequently developed 
striking extensive fibrotic parenchymal involvement. 
Follow-up scans were obtained in the first four surviving 
patients after a median interval from hospital discharge 
of 20 months. Patients with OP pattern at presentation 
developed ground-glass opacities both in new paren-
chymal territories and in previously consolidated areas. 
Three patients developed mild to moderate signs of 
fibrosis (traction bronchiectasis and mild parenchymal 
distortion), but no patient developed honeycombing. 
Representative images from baseline and follow-up CT 
scans of the first five patients are presented in Additional 
file 1: Figure S2.
A complete autoantibody panel was obtained, con-
sisting of antinuclear antibodies (ANA), anti-SSA/
Ro52, anti-SSB/LA, anti-ribonucleoprotein, anti-Scl70, 
anti-Smith, anti-Jo1, anti-centromere, anti-double-
stranded DNA, anti-neutrophil cytoplasmic antibody 
(ANCA), cyclic anti-citrullinated peptide and rheu-
matoid factor (RF). All patients had anti-SSA/Ro52; 
one patient had high titer ANA and anti-centromere 
autoantibodies and one was positive for anti-Jo1. Since 
no other causes of ILD were identified, extrathoracic 
symptoms were nonspecific and pulmonary manifesta-
tions were by far the most important, all patients met 
the criteria for IPAF.
All patients received immunosuppressive therapy while 
in ICU, after a median interval of 10 days from admission. 
Five of them received high doses of methylprednisolone 
(1000 mg/day for 3 days and then 1 mg/kg/day), followed 
by cyclophosphamide (10–15  mg/kg every 2–3  weeks); 
they also received iv immunoglobulin infusion, and two 
were treated with cyclosporine for inadequate response 
to cyclophosphamide. The remaining two patients were 
treated with methylprednisolone (1  mg/kg/day) without 
loading dose.
Five patients (71%) developed a ventilator-associated 
pneumonia, after a median time interval of 19 (10–31) 
days from admission: Pneumonia was caused by multid-
rug-resistant Gram-negative bacteria in three cases and 
by Aspergillus fumigatus in one case.
The median follow-up of the first four surviving patients 
was 21  months. At the last visit, forced vital capacity 
range was 77–112% and diffusing lung capacity for carbon 
monoxide 39–95% of predicted and no patient requires 
oxygen supplementation. Immunological follow-up exam-
inations showed that anti-SSA/Ro52 became negative in 
three out of four patients. Maintenance immunosuppres-
sive therapy with low-dose prednisone, azathioprine and 
mycophenolate is ongoing in three patients.
All IPAF patients, except from the two who died, gave 
their written informed consent to publication. Due to 
the retrospective nature of the study and since writ-
ten consent was obtained from the study patients, eth-
ics committee approval was waived according to local 
regulations.
Fig. 2 a Contrast-enhanced computed tomography scan of the thorax of Patient 5 at the level of the carina at ICU admission (slice thickness 
2 mm). The picture shows bilateral, diffuse ground-glass opacities with partial subpleural sparing and crazy-paving pattern. b Follow-up high-
resolution computed tomography scan of the thorax of Patient 4 at the level of the middle lobe (slice thickness 1 mm). The picture shows bilateral, 
mainly dorsal ground-glass opacities with reticulations and traction bronchiectasis
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Comparison between IPAF patients and control population
Table  3 shows the comparison of baseline characteristics 
and clinical outcome among the three patient groups. 
We did not find significant differences in regard to demo-
graphics, severity of hypoxemia (P/F ratio and Qs/Qt) and 
ventilator and respiratory mechanics parameters. IPAF 
patients tended to have a higher median SOFA score com-
pared to both control groups (11 vs 8 vs 8.5; p = 0.068) and 
a higher frequency of use of prone positioning (86 vs 53 vs 
43%; p = 0.197) and ECMO (71 vs 41 vs 25%; p = 0.176). 
ICU survival of IPAF patients was exactly equal to that of 
patients with a known risk factor (71%), while it was mark-
edly higher than that of the patients without risk factors 
(38%); however, due to the small number of patients, this 
difference was not statistically significant. Compared to 
the other subgroups, IPAF patients had significantly longer 
median ICU-LOS (54 vs 19 vs 15.5 days; p = 0.0045) and 
duration of IMV (49 vs 17 vs 15.5  days; p  =  0.031) and 
ECMO (53 vs 9.5 vs 28; p = 0.006).
In all the eight control patients without risk factors, 
microbiological and immunological screening resulted 
negative. Revision of chest CT scans and BAL per-
formed in these patients did not allow the identifica-
tion of a typical radiologic or cytomorphologic pattern, 
similarly to what observed IPAF patients. Of note, in all 
these patients a course of corticosteroid therapy was per-
formed, mainly for “nonresolving ARDS.”
Discussion
In this paper, we reviewed the clinical presentation, diag-
nostic workup and management of seven critically ill 
patients with IPAF. Our patients had an extremely severe 
clinical picture, with ARDS and multiple organ failure; 
they required prolonged mechanical ventilation and, in 
three cases, prolonged ECMO support. To the best of 
our knowledge, this is the first description of a cohort of 
patients with IPAF requiring ICU admission and inva-
sive ventilation. Compared to the control population of 
ARDS patients admitted in the same period, ICU survival 
of patients with IPAF was equal to that of patients with 
ARDS associated with a known risk factor, while it was 
markedly higher than that of the subgroup of patients 
without risk factors (71 vs 38%). Hence, in our case series, 
IPAF patients had similar baseline characteristics and 
outcome to patients with ARDS associated with a rec-
ognized clinical insult, while patients without a known 
risk factor had a worse outcome. Of note, despite simi-
lar severity of hypoxemia and impairment of respiratory 
mechanics, IPAF patients had a significantly higher ICU-
LOS and duration of IMV and required more frequently 
prone positioning and ECMO. Our findings confirm 
the data of Gibelin et al. [17] on a large series of ARDS 
patients: they observed that patients lacking exposure to 
common risk factors had a significantly higher mortal-
ity (66%) than other ARDS patients and found that the 
Table 3 Patient characteristics, severity scores at admission, ventilator and respiratory mechanics parameters at admis-
sion and clinical outcome data in the three groups of patients included in the study
Data are presented as absolute frequency (% of the included patients) or as median and interquartile range
IPAF interstitial pneumonia with autoimmune features, SAPS II Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment, PEEP positive end-
expiratory pressure, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, IMV invasive mechanical ventilation
* p < 0.05 versus IPAF group
ARDS with known risk factors No risk factors IPAF p
Gender (male) 54 (69%) 1 (25%) 4 (57%) 0.763
Age (years) 55 (45–67.25) 58.5 (38.5–72.25) 61 (50–66) 0.726
SAPS II 41.5 (31–50.5) 42 (35–59) 32 (32–37) 0.133
SOFA 8 (5.75–12) 8.5 (8–11) 11 (11–13) 0.068
PaO2/FiO2 (mmHg) 93 (67.75–125.25) 103 (62.75–150.75) 120 (80–141) 0.515
PEEP (mmHg) 12.5 (10–15) 10 (7.25–14.75) 12 (10–14) 0.303
Compliance (mL/cmH2O) 29.4 (24–37) 26.5 (16.25–43.5) 26 (14–30) 0.336
Intrapulmonary shunt (%) 35 (25–46.5) 33 (14.5–40.5) 35 (25.5–52.5) 0.588
Plateau pressure  (cmH2O) 28 (26–30) 27.5 (22.5–29.75) 26 (25–30) 0.796
Driving pressure  (cmH2O) 14 (11–18) 15.5 (10.25–21.25) 14 (12–18) 0.977
ECMO 32 (41%) 2 (25%) 5 (71%) 0.176
Tracheostomy 45 (58%) 3 (43%) 5 (71%) 0.557
Pronation 41 (53%) 3 (43%) 6 (86%) 0.197
Survival 55 (71%) 3 (38%) 5 (71%) 0.159
ICU length of stay (days) 19 (8.75–32.25)* 15.5 (5.5–35.75)* 54 (23–84) 0.045
ECMO duration (days) 9.5 (6–13)* 28 (8–48) 53 (17–63) 0.006
IMV duration (days) 17 (6–28.5)* 15.5 (5.5–34.25)* 49 (21–81) 0.031
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absence of known risk factors was independently associ-
ated with mortality (adjusted OR 2.06). Of note, De Prost 
et al. [18] recently published a secondary analysis on the 
cohort of ARDS patients without risk factors included 
in the LUNG SAFE study: ARDS without risk factors 
accounted for 8.3% of all ARDS cases and in 80% of these 
patients the etiology of ARDS was not identified.
Identification of the etiology of ILDs and their man-
agement remain a clinical challenge. The low incidence 
of ILD-associated ARF requiring ICU admission is a 
major obstacle to the assessment of outcome predictors 
and treatment optimization. Moreover, available studies 
report a high mortality among patients requiring inva-
sive MV [7, 19, 20], ranging from 47 to 89.7%. For these 
reasons, ICU physicians tend to be reluctant to admit 
patients with ILD of uncertain etiology and are even 
more reluctant to administer immunosuppressive drugs 
in the absence of a definite diagnosis of an autoimmune 
disease.
Many authors have underlined the need to categorize 
patients with prevalent pulmonary involvement in prob-
able autoimmune origin but with insufficient diagnostic 
criteria for a definite CTD. The rheumatologist would 
classify these patients as UCTD [8]; however, UCTD usu-
ally identifies patients with milder disease, nonspecific 
clinical features and low incidence of pulmonary involve-
ment [2, 9].
Thus, Vij proposed the definition AIF-ILD [12]: Diag-
nostic criteria are the presence of ILD associated with at 
least one symptom/sign and one abnormal serologic test. 
In Vij’s retrospective review of 200 patients with ILD, 63 
were classified as AIF-ILD and had significantly lower 
survival rates than patients with ILD associated with a 
definite CTD.
An alternative classification has been presented by Fis-
cher, who proposed the definition of LD-CTD for “cases 
where ILD has a rheumatologic flavor as supported by 
specific autoantibodies and yet does not meet criteria for 
a defined CTD based on the lack of adequate extratho-
racic features” [11]. However, ICU physicians are still 
not familiar with these diagnostic categories: Neither 
AIF-LD nor LD-CTD was considered in the large survey 
published by Dumas on 363 critically ill patients with sys-
temic rheumatic diseases [21].
In the attempt to create consensus, an ERS-ATS task 
force recently proposed the definition of IPAF [13], 
based on the combination of at least one feature from 
at least two of three diagnostic domains: clinical (spe-
cific extrathoracic manifestations), serologic (specific 
circulating autoantibodies) and morphologic (suggestive 
radiologic or histopathologic pattern). The main char-
acteristics of the classification are summarized in Addi-
tional file 1: Table S1.
All our patients but one were positive for anti-SSA/
Ro52: Ro52 is a protein implicated in the process of ubiq-
uitination and is upregulated at sites of autoimmune 
inflammation [22]. Several studies have demonstrated 
that anti-Ro52 is associated with ILD in patients with 
CTD, particularly in anti-synthetases syndromes [23]. 
Anti-tRNA synthetases were detected only in one of our 
patients, who had anti-Jo1 positivity but did not meet 
the diagnostic criteria for the anti-synthetase syndrome. 
However, diagnostic assays for anti-tRNA synthetases 
other than anti-Jo1 were not routinely available in our 
hospitals before 2015, and this might have reduced our 
ability to diagnose the disease.
As noted above, the definition of IPAF requires the 
presence of morphologic features, namely nonspecific 
interstitial pneumonia (NSIP), organizing pneumonia 
(OP) or lymphoid interstitial pneumonia (LIP) patterns 
at HRTC or lung biopsy [13]. Histologic and radiologic 
presentation in these patients is unspecific and vari-
able, as recently demonstrated by Omote in a series of 44 
patients with LD-CTD who underwent open lung biopsy 
[24]: the major histologic patterns were usual intersti-
tial pneumonia (UIP) followed by NSIP, and UIP pattern 
was associated with worse prognosis. Similar findings 
were described in two recent studies on larger cohorts of 
patients meeting the diagnostic criteria for IPAF: More 
than half of the patients had a high-confidence diagno-
sis of UIP pattern on CT that was associated with worse 
prognosis particularly when associated with honeycomb-
ing or pulmonary artery enlargement [25–27]. We did 
not identify any specific radiologic (CT scan) or cytologic 
(BAL) findings in IPAF patients; a significant lympho-
cytosis in BAL, which strongly suggests an autoimmune 
etiology, was indeed observed only in three patients. 
Interestingly, none of these patients had a UIP pattern on 
CT scan, and this may explain the good clinical outcome 
of our cohort. Interestingly, lack of a typical CT scan and 
BAL findings was observed also in control patients with-
out common risk factors. However, we acknowledge that 
the correlation between lung histology and radiologic 
pattern at CT scan may be quite poor, especially in criti-
cally ill patients undergoing mechanical ventilation.
One important limitation of our study is the lack of 
histologic data, due to the high risk of serious complica-
tions when a lung biopsy is performed during mechani-
cal ventilation and ECMO. We acknowledge that lung 
histology is extremely helpful in patients with ARDS of 
unknown origin or in cases of nonresolving ARDS, since 
it can provide important diagnostic and prognostic infor-
mation and guide patient management [28, 29]. Another 
limitation resides in the very small number of patients, 
which limits statistical power of the analysis even in case 
of large differences among the subgroups; moreover, the 
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limited sample size precluded the possibility of perform-
ing a multivariate analysis of risk factors associated with 
mortality.
To the best of our knowledge, this is the first report of 
a series of critical patients fulfilling the diagnostic criteria 
for IPAF requiring ICU admission for ARDS. The num-
ber of patients is small, but the patient population is very 
well characterized and the clinical condition is rare. We 
think that our patient series demonstrates that the pos-
sibility of an autoimmune etiology and in particular the 
diagnosis of IPAF must be considered in any critically ill 
patient with “ARDS” according to the Berlin definition 
criteria but without a known risk factor. Once the diag-
nosis is established, these patients should receive a “full 
code” treatment, including ECMO if necessary, especially 
if the CT scan does not show a UIP pattern with associ-
ated signs of fibrosis or pulmonary hypertension. Man-
agement of IPAF patients is really challenging, but they 
can have a very good outcome if the appropriate therapy 
is instituted: immunosuppressive treatment can lead to 
a significant improvement in pulmonary manifestations 
and should be initiated as soon as an infectious cause has 
been excluded.
However, selecting the appropriate diagnostic and ther-
apeutic strategy is extremely complex and requires a mul-
tidisciplinary approach: the intensivist should become 
part of a team together with the rheumatologist, the pul-
monologist, the radiologist and the pathologist.
Conclusions
 Interstitial pneumonia with autoimmune features (IPAF) 
is a rare autoimmune form of interstitial lung disease 
that can present acutely with ARDS and multiple organ 
failure, requiring ICU admission and advanced life sup-
port measures (included ECMO, if needed). This diag-
nosis should be considered in any patient presenting 
with interstitial pneumonia and ARDS lacking exposure 
to common risk factors for ARDS. In our small cohort 
of patients, the clinical response to immunosuppres-
sive therapy was good, with a survival rate equal to that 
of patients with ARDS associated with a known clinical 
insult. Findings of the present study need to be confirmed 
prospectively on larger patient series.
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